Receptos to Hold Fourth Quarter and Year End 2013 Financial Results Conference Call and Webcast
February 27, 2014 08:00 ET
|
Receptos, Inc.
SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will...
Receptos Announces Closing of Underwritten Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 14, 2014 09:46 ET
|
Receptos, Inc.
SAN DIEGO, Jan. 14, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
Receptos Announces Pricing of Underwritten Public Offering of Common Stock
January 08, 2014 21:41 ET
|
Receptos, Inc.
SAN DIEGO, Jan. 8, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
Receptos Begins Enrollment of Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
January 06, 2014 16:05 ET
|
Receptos, Inc.
– Pivotal Phase 3 Trial is Underway with First Patients Randomized in December 2013 –
– Topline Results of Phase 2 Still Expected in Mid-2014...
Receptos Announces Proposed Underwritten Public Offering of Common Stock
January 06, 2014 16:05 ET
|
Receptos, Inc.
SAN DIEGO, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
Receptos and Ono Pharmaceuticals Expand Collaboration Agreement to Include Transfer of Receptos GPCR Technology Platform
December 10, 2013 16:05 ET
|
Receptos, Inc.
SAN DIEGO, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT) announced today that Ono has elected to amend and expand the existing collaboration agreement between the parties to include...
Receptos to Initiate Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
December 05, 2013 08:00 ET
|
Receptos, Inc.
– Data from Interim Analysis of Phase 2 Trial Provide Support to Advance Program –
– Interim Data Consistent with RPC1063 Differentiation Profile –...
Christian Waage Appointed General Counsel of Receptos
November 26, 2013 08:00 ET
|
Receptos, Inc.
SAN DIEGO, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT) announced today that Christian Waage has been appointed Senior Vice President and General Counsel of the Company.
Mr. Waage...
Receptos to Present at 2013 Credit Suisse Healthcare Conference
November 11, 2013 08:00 ET
|
Receptos, Inc.
SAN DIEGO, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Reports Third Quarter 2013 Financial Results
October 30, 2013 16:22 ET
|
Receptos, Inc.
- Phase 2 trial of RPC1063 in relapsing multiple sclerosis has completed enrollment; interim results to be reviewed in Q4 2013 -
- Phase 2 trial of RPC1063 in ulcerative colitis continues to...